Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro.
about
Targeting the latent reservoir to achieve functional HIV cureRheumatoid arthritis in patients with HIV: management challengesImmunologic strategies for HIV-1 remission and eradication.Replication competent virus as an important source of bias in HIV latency models utilizing single round viral constructs.Immuno-modulatory strategies for reduction of HIV reservoir cells.The impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasmsTemporal transcriptional response to latency reversing agents identifies specific factors regulating HIV-1 viral transcriptional switchIdentification of novel HIV-1 dependency factors in primary CCR4(+)CCR6(+)Th17 cells via a genome-wide transcriptional approach.Janus kinase inhibition suppresses PKC-induced cytokine release without affecting HIV-1 latency reversal ex vivo.Residual inflammation and viral reservoirs: alliance against an HIV cure.Chloroquine and beyond: exploring anti-rheumatic drugs to reduce immune hyperactivation in HIV/AIDS.The therapeutic landscape of HIV-1 via genome editingThe Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model.JAK-STAT Signaling Pathways and Inhibitors Affect Reversion of Envelope-Mutated HIV-1.Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice.Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors.
P2860
Q26745923-8E891BA3-F06F-4AD7-8F72-60D18F7AE979Q28075624-999E5DB1-64A7-40D5-8C49-D983CBB32C71Q33896523-BD5F7EF4-F3D6-49BA-A4FA-816F74C39CB2Q34143903-BDA1FA76-76AE-4A1A-944B-DA4C591BE14FQ35329923-E3D6EBD2-502B-4475-B3A8-A45DC152005EQ35841839-ECA5CDB5-25D3-4AFE-8C43-39AC202B02EFQ36125264-880A580E-EEB5-46D9-8775-5F7155A7A6F3Q36364264-4CC215E3-DD17-4C61-830D-95F1951DD47AQ37522861-74CDDDBA-C1DC-4199-8289-54EC17D25824Q38269458-0AD472F7-98A9-47F9-90A9-1EE999A89380Q38530430-6CAF1ABE-50EA-4988-8487-0F9EC71EC060Q39153976-8781B3AE-F9A8-4893-B336-BF240796F7D2Q40018266-F9B3BA75-1187-44C5-B2EB-5C68DECF6D60Q40331435-D0F1FCB5-8E19-4774-A23A-82BE666EC042Q47148643-41A0E6C8-D421-4526-A827-57276B57F5C5Q47561974-F85B6D2B-F605-4BC9-AFCB-16B6A349FA98
P2860
Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Ruxolitinib and tofacitinib ar ...... d virus reactivation in vitro.
@ast
Ruxolitinib and tofacitinib ar ...... d virus reactivation in vitro.
@en
type
label
Ruxolitinib and tofacitinib ar ...... d virus reactivation in vitro.
@ast
Ruxolitinib and tofacitinib ar ...... d virus reactivation in vitro.
@en
prefLabel
Ruxolitinib and tofacitinib ar ...... d virus reactivation in vitro.
@ast
Ruxolitinib and tofacitinib ar ...... d virus reactivation in vitro.
@en
P2093
P2860
P356
P1476
Ruxolitinib and tofacitinib ar ...... nd virus reactivation in vitro
@en
P2093
Catherine Montero
Christina Gavegnano
Mervi Detorio
Vicente Planelles
P2860
P304
P356
10.1128/AAC.02496-13
P407
P577
2014-01-13T00:00:00Z